U.S. Markets closed

Achieve Life Sciences, Inc. (ACHV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.78+0.04 (+0.52%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.74
Open7.78
Bid7.74 x 800
Ask8.20 x 800
Day's Range7.58 - 7.80
52 Week Range6.85 - 18.26
Volume115,171
Avg. Volume241,128
Market Cap73.522M
Beta (5Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-5.02
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.83
  • Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Use
    ACCESSWIRE

    Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Use

    SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / July 22, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) to evaluate the use of cytisinicline as a treatment for cessation of nicotine e-cigarette use.

  • ACHV: Longer Patents, Higher Valuation
    Zacks Small Cap Research

    ACHV: Longer Patents, Higher Valuation

    By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) has been active since our first quarter update published several weeks ago. We saw a $23 million capital raise, the allowance of new patents and contaminant troubles related to Pfizer’s (NYSE:PFE) smoking cessation product. Results from an independent study conducted in Australia

  • ACHV: Target Up On Longer Patent Life
    Zacks Small Cap Research

    ACHV: Target Up On Longer Patent Life

    By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) has experienced a considerable of activity since our first quarter update published several weeks ago. We saw a $23 million capital raise, the allowance of new patents and contaminant troubles related to Pfizer’s (NYSE:PFE) smoking cessation product, Chantix. In addition, Achieve